SIMBA Capsule for Multiple Sclerosis

Overseen By Carlos Camara-Lemarroy

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Nimble Science Ltd.

Must not be taking: Opioids, Prokinetics, Anticholinergics, others

Disqualifiers: Swallowing disorders, Crohn's, Cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

60 Participants Needed

Trial Summary

What is the purpose of this trial?

To access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in MS compared to HC that could be used as biomarkers for MS.

Research Team

Carlos Camara-Lemarroy

Principal Investigator

University of Calgary

Eligibility Criteria

This trial is for adults aged 18-60 with Multiple Sclerosis (either relapsing-remitting or secondary progressive) or healthy individuals living with them. Participants must not have used antibiotics, colon cleanses, or certain other medications recently and should be able to swallow normally without risk of intestinal blockage.

Inclusion Criteria

I am between 18 and 60 years old.

I have been diagnosed with Multiple Sclerosis or I am a healthy individual living with someone who has MS.

I haven't taken antibiotics or done a colon cleanse in the last 2 weeks.

Exclusion Criteria

I have fewer than 2 bowel movements a week.

I haven't taken drugs that affect my stomach movement or acidity in the last week.

Known swallowing disorders

Treatment Details

Interventions

• SIMBA Capsule

Trial Overview The SIMBA Capsule is being tested to see if it can identify unique gut microbiome patterns in the small intestine that could serve as biomarkers for Multiple Sclerosis when compared to healthy controls.

Participant Groups

Group I: Single Arm Experimental Treatment 1 Intervention

Participant swallows and retrieves capsule in stool. Intestinal fluid samples collected by SIMBA capsules from the MS and HC participants, along with a fecal and blood samples, will be used for gut microbiome, viral and metabolomic analysis.

Who Is Running the Clinical Trial?

Nimble Science Ltd.

Lead Sponsor

Trials

11

Recruited

570+

IGY Life Sciences

Collaborator

Trials

1

Recruited

60+